BEAT Overview

HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.

Wall Street analysts forecast BEAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAT is5.83 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Heartbeam Inc revenue for the last quarter amounts to -4.72M USD, decreased -14.32

Heartbeam Inc. EPS for the last quarter amounts to -3856000.00 USD, decreased -13.87

Heartbeam Inc (BEAT) has 16 emplpoyees as of May 15 2026.

Today BEAT has the market capitalization of 57.73M USD.